a-cell: regulatory considerations
Published 11 months ago • 755 plays • Length 1:02:31Download video MP4
Download video MP3
Similar videos
-
59:51
a-gene: regulatory considerations
-
1:02:39
a-cell: manufacturing of cell-based therapies
-
28:59
introduction and industry update - cell & gene state of the industry briefing 2024
-
14:48
overview of the alliance for regenerative medicine’s initiatives
-
59:16
opportunities for regulatory convergence in cell and gene therapy
-
47:07
keynote: molecular regulation of stem cell quiescence & activation
-
1:01:40
cell therapy treatments for covid-19
-
46:39
what’s next for cell and gene therapies in 2023 and beyond
-
15:43
saxocell
-
52:32
panel: when does investing in cell and gene therapy make business sense?
-
1:00:20
plenary session: implications of commercialization: what does approval mean?
-
1:00:38
critical supply chain and logistics considerations for cell and gene therapy management
-
1:01:05
a-cell: generation of qtpp, risk assessment and critical quality attribute identification
-
16:25
fda’s efforts to advance the development and approval of cellular and gene therapies
-
58:25
panel: current realities of make vs. buy for cell & gene therapy manufacturing
-
1:02:29
panel: safety and efficacy considerations for cell and gene therapies
-
1:02:11
a-cell: facility design and manufacturing operations
-
1:01:03
a-gene: comparability
-
1:00:55
addressing potency assay development challenges
-
3:38
regulatory challenges & strategies for regen med companies
-
24:04
2023 industry update at the cell & gene state of the industry briefing